好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Determining the Prevalence of Sleep Disturbances in Autoimmune Encephalitis
Autoimmune Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
15-004
Determine the prevalence and subtypes of sleep disturbances in a cohort of patients with autoimmune encephalitis diagnosed and managed at our tertiary care hospital.
Autoimmune encephalitis (AE) is increasingly recognized as an important cause of subacute cognitive decline, seizures, and encephalopathy, with an ever-broadening clinical phenotype. Sleep disturbances are reported in patients with AE, including rapid eye movement (REM) sleep behavior disorder, hypersomnia, fragmented sleep, and sleep-disordered breathing; however, the prevalence of sleep disturbances and contributions to outcomes in AE patients remains unknown. There is a need to determine the prevalence of sleep pathology in patients with AE, and to clarify the relationship between specific autoantibodies and sleep disturbances.
Clinical history, results of serum and cerebrospinal fluid testing, electroencephalography, and neuroimaging were reviewed from 26 patients with AE diagnosed and managed at our tertiary care hospital. Polysomnography was performed in AE patients with clinical indications.
The median age of AE patients was 53 years (range, 18-83). Autoantibodies against intracellular antigens (including Ma and Hu autoantibodies) were identified in 6/26 (23%) patients, while autoantibodies against cell-surface antigens (including NMDAR and LGI1) were identified in 20/26 (77%) patients. New sleep complaints were reported in 19/26 (73%) patients with AE, including gasping or snoring (9/19, 47%), dream enactment behavior (6/19, 32%), insomnia (5/19, 29%), hypersomnia (4/19, 21%), other parasomnias (4/19, 21%), and sleep/wake confusional states (2/19, 11%). Polysomnography showed reduced total sleep time, stage 3 and REM sleep, and prominent sleep fragmentation.
Sleep disturbances are prevalent in AE, warranting active surveillance for sleep disturbances in patients with AE. Improved identification and treatment of sleep disorders may reduce morbidity associated with AE and improve long-term outcomes.
Authors/Disclosures
Margaret Blattner, MD (Beth Israel Deaconess Medical Center)
PRESENTER 		Dr. Blattner has nothing to disclose.
No disclosure on file
Bob Bucelli, MD, PhD (Washington University) Dr. Bucelli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen . Dr. Bucelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bucelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Bucelli has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Hamilton Weber. Dr. Bucelli has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for O'Bryan Brown and Toner. Dr. Bucelli has stock in Neuroquestions.com. An immediate family member of Dr. Bucelli has stock in Neuroquestions.com. The institution of Dr. Bucelli has received research support from Biogen. The institution of Dr. Bucelli has received research support from Ionis.
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic) Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has or had stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Amgen Pharmaceuticals. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with 好色先生. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing 好色先生, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Ionis Pharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Case Development + Presentation (video) with PeerDirect (P\S\L Group). Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development / Presentation (non-CME) with MJH Life Sciences (NeurologyLive). Dr. Day has a non-compensated relationship as a Clinical Director with Anti-NMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.